Skip to main content
SpringerLink
Log in

Antirheumatika und Antiphlogistika

  • Chapter
Arzneiverordnungs-Report 2015

  • 1938 Accesses

Zusammenfassung

Bei den Verordnungen der Antirheumatika und Antiphlogistika dominieren auch 2014 mit klarem Abstand die nichtsteroidalen Antiphlogistika. Unter diesen steht Ibuprofen weiterhin an erster Stelle vor Diclofenac in der Verordnungshäufigkeit. Die Verordnungen der zwei auf dem Markt verbliebenen selektiven Cyclooxygenase-2-Hemmer sind erneut gegenüber dem Vorjahr angestiegen. Insgesamt machen die COX-2-Hemmstoffe auch 2014 jedoch nur gut 10% der Gesamtverordnungen bei den nichtsteroidalen Antiphlogistika aus.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Alcorn N, Saunders S, Madhok R (2009): Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 32: 1123–1134

    Article  CAS  PubMed  Google Scholar 

  • Bannwarth B, Richez C (2011): Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf 10: 123–131

    Article  CAS  PubMed  Google Scholar 

  • Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al (2000): Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520–1528

    Article  CAS  PubMed  Google Scholar 

  • Cannon CP, Curtis SP, Fitzgerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, Van Der Heijde D, Erdmann E, Laine L (2006): Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368: 1771–1781

    Article  CAS  PubMed  Google Scholar 

  • Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW,

    Google Scholar 

  • Chung SC, Sung JJ (2002): Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104–2110

    Article  PubMed  Google Scholar 

  • Charatan F (2002): Arthritis drug should be removed from market, says consumer group. Brit Med J 324: 86–9

    Article  Google Scholar 

  • Coxib and traditional NSAID Trialists' (CNT) Collaboration (2013): Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382: 769–779

    Article  Google Scholar 

  • Cryer B, Feldman M (1998): Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104: 413–421

    Article  CAS  PubMed  Google Scholar 

  • Day R (2002): Another selective COX-2 inhibitor: more questions than answers? J Rheumatol 29: 1581–1582

    PubMed  Google Scholar 

  • Dreser H (1899): Pharmakologisches über Aspirin (Acetylsalicylsaüre). Pflügers Arch 76: 306–318

    Article  CAS  Google Scholar 

  • European Medicines Agency (2005): Public Statement. European Medicines Agency announces regulatory action on COX-2 inhibitors. Publiziert am 17. Februar 2005 unter: www.emea. eu.int/htms/hotpress/d6275705.htm

  • European Medicines Agency (2007): Press release. European Medicines Agency recommends restricted use for piroxicam. Publiziert am 25. Juni 2007 unter: www.emea.europa.eu/pdfs/>human/press/pr/26514407en.pdf

  • European Medicines Agency (2012): European Medicines Agency finalises review of recent published data on cardiovascular safety of NSAIDs. Press release 19.10.2012 FDA-Statement (2004): FDA-Statement on Naproxen. Publiziert am 20. Dezember 2004 unter: www.fda.gov/bbs/topics/news/2004/new01148.html

  • Fu JY, Masferrer JL, Seibert K, Raz A, Needlemam P (1990): The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265: 16737–16740

    CAS  PubMed  Google Scholar 

  • Gemeinsamer Bundesausschuss (2012): Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über die Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage III Nummer 18 - Antiphlogistika oder Antirheumatika in fixer Kombination mit anderen Wirkstoffen vom 22. November 2012. Internet: http://www.g-ba.de/downloads/40-268- 2120Z2012-11-22_AM-RL3_Nr18-Antirheumatika_TrG.pdf

  • Graham DY, White RH, Moreland LW, Schubert TT, Katz R, Jaszewski R, Tindall E, Triadafilopoulos G, Stromatt SC, Teoh LS (1993): Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 119: 257–262

    Article  CAS  PubMed  Google Scholar 

  • Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD Logan RF, Murphy M, Vessey MP, Colin-Jones DG (1994): Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs. Lancet 323: 1075–1052

    Article  Google Scholar 

  • Lin J, Zhang W, Jones A, Doherty M (2004): Efficacy of topical non-steroidal antiinflammatory drugs in the treatment of osteoarthritis: metaanalysis of randomised controlled trials. Brit med J 329: 324–326

    Google Scholar 

  • Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR (1993): Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygen- ase. Proc Natl Acad Sci USA 90: 11693–11697

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Patel AM, Moreland LW (2010): Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther 4: 263–278

    PubMed Central  PubMed  Google Scholar 

  • Patrone C, Baigent C (2014): Nonsteroidal anti-inflammatory drugs and the heart. Circulation 129: 907–916

    Article  Google Scholar 

  • Piroxicam Rote-Hand-Brief (2007): Neue Anwendungsbeschränkungen für die systemische Anwendung von Piroxicam aufgrund gastrointestinaler Nebenwirkungen und Hautreaktionen. Internet: www.akdae.de/20/40/Archiv/2007/40-20071011.pdf

  • Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, Herrero-Beaumont G, Moore A, Eliakim R, Haim M, Reginster JY (2004): Time dependent risk of gastrointestinal compli- cations induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 63: 759–766

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux- Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D (2014): EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73: 492–509

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators (2005): Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071–1080

    Article  CAS  PubMed  Google Scholar 

  • Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P (2011): Cardiovascular safety of non-steroidal anti-inflammatory drugs: network metaanalysis. Brit Med J 342: c 7086 1–11

    Google Scholar 

  • Vane JR (1971): Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231: 232–235

    Article  CAS  PubMed  Google Scholar 

  • Wolfe MM, Lichtenstein DR, Singh G (1999): Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888-1899 1–6

    Google Scholar 

Download references

Authors
  1. Rainer H. Böger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerhard Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2015 Springer-Verlag Berlin Heidelberg

    About this chapter

    Cite this chapter

    Böger, R., Schmidt, G. (2015). Antirheumatika und Antiphlogistika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2015. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47186-9_15

    Download citation

    • DOI: https://doi.org/10.1007/978-3-662-47186-9_15

    • Publisher Name: Springer, Berlin, Heidelberg

    • Print ISBN: 978-3-662-47185-2

    • Online ISBN: 978-3-662-47186-9

    • eBook Packages: Medicine (German Language)

    Publish with us

    Policies and ethics

    Search

    Navigation